1. It’s Test Prep Week! Visit the Test Prep Forums to learn about test prep products and services, ask questions in test-related AMA threads, take advantage of exclusive SDN member discounts, and enter to win free stuff!
Whether you’re preparing for the USMLE, COMLEX, NBDE or APMLE, Test Prep Week Exhibitors can help you ace your boards!

Goodbye PD-L1?

Discussion in 'Pathology' started by WEBB PINKERTON, May 25, 2017.

  1. SDN is made possible through member donations, sponsorships, and our volunteers. Learn about SDN's nonprofit mission.
  1. WEBB PINKERTON

    WEBB PINKERTON 5+ Year Member

    1,178
    106
    Dec 16, 2010
    Is PD-L1 testing going to be a thing of the past with new FDA approval for Keytruda that just came out?
     
  2. SDN Members don't see this ad. About the ads.
  3. pathslides

    pathslides

    88
    17
    Aug 7, 2016
    Oncologists will just ask for MSI testing on everything now.
     
    Autopsy101 likes this.
  4. coroner

    coroner Peace Sells...but who's buying? 10+ Year Member

    451
    109
    Aug 3, 2007
    22 Acacia Avenue
    Physician
    PD-L1 testing is here to stay regardless of FDA approval of Keytruda for multiple reasons:

    1) It’s still part of the NCCN guidelines for squamous cell carcinoma of the lung

    2) It’s almost always the first test ordered for NSCLC w/ or w/o EGFR vs ALK, and ROS.

    3) Different assays for PD-L1 can affect the type of immunotherapy given e.g. Keytruda vs Tecentriq.

    4) Clinicians are still going to want all info available at their disposal

    Not to mention, it’s a valid test we can interpret and bill for, sort of like when everybody started doing HER-2. So pathologists will be more than happy to continue to do so with PD-L1.
     
    Last edited: Jun 29, 2017
    medgator likes this.
  5. coroner

    coroner Peace Sells...but who's buying? 10+ Year Member

    451
    109
    Aug 3, 2007
    22 Acacia Avenue
    Physician
    You may have a point though. Although I still think PD-L1 will still be used, with the FDA approval of Keytruda, the reimbursement rates of this expensive treatment no longer hinges on PD-L1 testing because it is now a complementary test instead of a companion test. So, testing it could either stabilize or possibly decrease, but such changes probably won't become evident for another few years. Not sure what the future holds...
     
  6. WEBB PINKERTON

    WEBB PINKERTON 5+ Year Member

    1,178
    106
    Dec 16, 2010
    If we weren't playing with monopoly money, it would decrease. We all see overkill on a daily basis in medicine so look for testing to stabilize or increase. The vendors and labs have to keep the machine fed so there can't be a reduction in demand.
     

Similar Threads
  1. ItsGavinC
    Replies:
    36
    Views:
    2,770
  2. joelmamchur
    Replies:
    8
    Views:
    770
  3. Verum
    Replies:
    36
    Views:
    2,938
Loading...

Share This Page